Does Microdosing Affect Your Heart? Blood Pressure, Heart Rate & What the Research Says

Psilocybin microdosing has become increasingly popular, but one important question often gets overlooked: what does repeated exposure to small amounts of psilocybin mean for your cardiovascular system?

The short answer is that psilocybin can temporarily affect cardiovascular measurements, particularly blood pressure and, to a lesser extent, heart rate. These effects have been documented most clearly in studies using larger, supervised doses of psilocybin. Research specifically examining the cardiovascular effects of repeated mushroom microdosing is much more limited.

That distinction matters.

Current evidence does not establish that psilocybin microdosing causes long-term heart damage. At the same time, there is not enough long-term evidence to say that repeated microdosing is completely free of cardiovascular risk. A 2026 systematic review of psilocybin mushroom and truffle microdosing found only 11 eligible studies involving 3,262 adults and concluded that the overall certainty of evidence remains low, with substantial variation in dosing protocols and preparations. [1]

For people interested in harm reduction, the most useful approach is therefore neither alarmism nor reassurance. It is understanding what researchers have actually observed, what remains uncertain, and why the difference between a clinical psilocybin study and real-world mushroom microdosing matters.

How Can Psilocybin Affect the Cardiovascular System?

Psilocybin is converted in the body into psilocin, which interacts with several serotonin receptors throughout the nervous system and body.

Serotonin signaling is involved in a number of physiological processes, including cardiovascular regulation. As a result, psilocybin can produce measurable changes in blood pressure and heart rate.

These effects are generally considered part of the acute physiological response to psilocybin rather than evidence of permanent cardiovascular damage.

A systematic review of psilocybin in psychiatric and substance-dependence research found that psilocybin was associated with modest increases in blood pressure and heart rate. The review included 16 clinical studies and noted that these cardiovascular changes were generally transient. [2]

A separate 2024 systematic review and meta-analysis of psychedelic safety data found increased risk of elevated heart rate and systolic and diastolic blood pressure during the acute phase following psychedelic administration. Serious adverse events were uncommon in the controlled research settings included in the analysis. [3]

However, most of this research involves larger doses of psilocybin than those typically described as microdoses.

That is one of the most important limitations to keep in mind when interpreting the evidence.

Does Psilocybin Raise Blood Pressure?

Yes. Temporary increases in blood pressure have been observed in controlled psilocybin studies.

A 2024 systematic review and meta-analysis of therapeutic-dose psilocybin studies found that elevated blood pressure was significantly more common following psilocybin administration than placebo, with a relative risk of 2.29. [4]

A systematic review of psilocybin's tolerability similarly reported modest increases in blood pressure and heart rate. In one study included in that review, a participant received an antihypertensive medication for sustained hypertension during a psilocybin session. [2]

More recently, a 2026 cardiovascular review synthesized data from clinical trials and reported average increases of approximately 19 mmHg in systolic blood pressure and 8.7 mmHg in diastolic blood pressure following supervised psilocybin administration. The largest differences generally occurred around 60–90 minutes after dosing and typically resolved within several hours. [5]

But these numbers should not be interpreted as typical microdose effects.

The doses used in many of the studies contributing to these estimates were substantially larger than the amounts generally used for mushroom microdosing.

In other words:

Research shows that psilocybin can temporarily increase blood pressure. It does not establish that a particular mushroom microdose will raise your blood pressure by a particular amount.

That distinction is especially important because mushroom products can contain variable amounts of psilocybin.

What About Heart Rate?

Psilocybin can also affect heart rate, although the changes appear to be smaller and less consistent than the effects observed for blood pressure.

The 2026 cardiovascular review found that heart-rate effects were generally less pronounced and less consistent than blood-pressure changes. [5]

A pooled analysis of psilocybin safety data published in 2024 provides another example. Among 113 psilocybin administrations in 85 healthy participants, heart rate exceeded 100 beats per minute in 7% of administrations. [6]

Again, those participants received 15–30 mg of psilocybin, which is much larger than a typical mushroom microdose.

This is therefore useful evidence that psilocybin can influence cardiovascular activity, but it should not be interpreted as a 7% risk estimate for people taking mushroom microdoses.

What about palpitations?

A noticeable heartbeat or temporary increase in heart rate can occur during psychedelic experiences, but a new or severe cardiovascular symptom should not automatically be attributed to psilocybin.

Chest pain, fainting, severe shortness of breath, sustained or severe palpitations, or other symptoms that feel medically urgent warrant appropriate medical evaluation rather than assuming they are simply a normal effect of microdosing.

What Do We Actually Know About Microdosing and the Heart?

This is where the evidence becomes much less certain.

Research on psilocybin microdosing specifically is considerably smaller than the research on therapeutic or psychedelic doses.

A 2025 systematic review examining side effects of LSD and psilocybin microdosing identified 31 studies. The review found that reported adverse effects were generally mild and short-lived, but increased blood pressure was among the commonly reported physiological effects. The authors also emphasized substantial heterogeneity in how side effects were measured and the short duration of many studies. [7]

A 2026 systematic review focused specifically on psilocybin mushroom and truffle microdosing identified only 11 eligible studies involving 3,262 adults. The researchers found substantial variation in dosing protocols, preparations, outcome measurements, and study quality. They concluded that the certainty of the evidence was low and that causal effects could not yet be established. [1]

This leaves us with an important evidence gap.

We have more information about:

• The short-term cardiovascular effects of psilocybin

• Blood-pressure changes following larger doses

• Heart-rate changes following larger doses

• Cardiovascular effects in carefully selected research participants

We have much less information about:

• Cardiovascular effects of repeated mushroom microdosing

• Microdosing over several years

• The effect of different dosing schedules on cardiovascular health

• People with existing cardiovascular conditions

• Variable-potency mushroom preparations

• Long-term effects of repeated exposure to serotonergic psychedelics

A 2026 review of psychedelic safety specifically identified long-term cardiac safety as unresolved, including in the context of microdosing. [8]

Why Can't We Simply Apply Full-Dose Psilocybin Research to Microdosing?

This is one of the most important distinctions in psychedelic safety research.

Clinical trials generally involve carefully screened participants, standardized doses, controlled environments, and medical monitoring.

Real-world mushroom microdosing can look very different.

Someone may be using:

• A mushroom preparation with variable psilocybin concentration

• A capsule or dried mushroom material rather than pharmaceutical-grade psilocybin

• A repeated dosing schedule

• Other medications or substances

• Caffeine, alcohol, cannabis, or other psychoactive substances

• Microdoses without cardiovascular monitoring

The 2026 cardiovascular review specifically noted that naturally derived mushroom products can have substantial variation in active-alkaloid content. [5]

The 2026 microdosing systematic review also found extreme heterogeneity in dosing protocols and preparations across the available research. [1]

That means the phrase "psilocybin microdose" doesn't necessarily describe a standardized exposure.

Two people can consume the same weight of mushroom material and potentially receive different amounts of psilocybin.

What Is the 5-HT2B Receptor, and Why Does It Matter?

If you've researched psychedelic cardiovascular safety, you've probably encountered the 5-HT2B receptor.

The reason researchers pay attention to it is that sustained activation of 5-HT2B signaling has been implicated in drug-induced heart-valve disease with certain medications.

Psilocin interacts with several serotonin receptors, including serotonin receptors in the 5-HT2 family. This has led researchers to investigate whether repeated psychedelic exposure could theoretically have effects on cardiac valves.

That is a legitimate scientific question—but it is important not to turn a biological mechanism into a demonstrated clinical outcome.

Does psilocybin microdosing cause heart-valve disease?

There is currently no clinical evidence establishing that it does.

A 2023 review specifically examining chronic psychedelic microdosing and valvular heart disease noted that long-term safety was poorly characterized and that the potential risk was based on 5-HT2B receptor activity. [9]

A 2024 review similarly discussed the theoretical relationship between psychedelic microdosing, 5-HT2B signaling, and cardiac fibrosis or valvulopathy, while noting that the clinical risk had not been established in controlled studies. [10]

More recently, a 2026 systematic review examined psychedelic-associated cardiac consequences and 5-HT2B-mediated valvular disease. Importantly, the authors found no studies specifically demonstrating psilocybin-induced valvular disease in their review. [11]

The 2026 cardiovascular review reached a similar conclusion: a 5-HT2B-mediated valvular concern remains biologically plausible under chronic exposure, but clinical valvular injury from psilocybin has not been established. [5]

The distinction is important

There is a difference between:

"This biological pathway exists and deserves research."

and

"This substance has been shown to cause heart-valve disease."

The first statement is supported by current evidence.

The second is not established for psilocybin microdosing.

Does Microdosing Cause Long-Term Heart Damage?

At this point, research cannot provide a definitive yes or no.

There is evidence of temporary cardiovascular effects following psilocybin administration.

There is also a plausible biological reason for researchers to investigate the effects of repeated serotonergic exposure.

But there is not currently sufficient longitudinal evidence to conclude that repeated psilocybin microdosing causes permanent cardiovascular damage.

The latest research therefore supports a more nuanced conclusion:

The long-term cardiovascular safety of repeated psilocybin microdosing remains an open research question.

This is not the same as saying that long-term harm has been demonstrated.

It also isn't the same as saying that long-term harm has been ruled out.

The distinction matters because the absence of evidence for harm is not equivalent to evidence that there is no harm—particularly when long-term studies are limited.

What About People With High Blood Pressure or Heart Conditions?

People with cardiovascular conditions deserve additional caution because psilocybin can temporarily affect blood pressure and heart rate.

Clinical psychedelic studies commonly use screening criteria that exclude people with certain significant cardiovascular conditions. As a result, findings from healthy or carefully screened research participants cannot automatically be generalized to people with heart disease or uncontrolled hypertension. [5]

If you have:

• High blood pressure

• A heart rhythm disorder

• Known heart disease

• Heart-valve disease

• A history of significant cardiovascular events

• Another cardiovascular condition

it is reasonable to discuss psychedelic use with a qualified healthcare professional who knows your medical history.

This is particularly important if you take medications that affect blood pressure, heart rate, or cardiovascular function.

Do not stop or change prescribed cardiovascular medication in order to microdose.

What About Blood Pressure Medication?

The interaction between psilocybin and specific blood-pressure medications has not been adequately studied across the wide range of medications people use in everyday life.

Because psilocybin can temporarily affect blood pressure, combining it with medications that also influence cardiovascular function may require individualized consideration.

This is one area where broad internet claims can be misleading.

Rather than assuming that a particular medication combination is either "safe" or "dangerous," it is better to consider:

1. The specific medication

2. The dose

3. The person's cardiovascular history

4. Other medications or substances

5. The amount and frequency of psilocybin exposure

For more information about potential medication interactions, see our [Psilocybin Drug Interactions Guide].

What About Caffeine, Cannabis, Alcohol and Other Substances?

Combining substances can make it more difficult to predict what is responsible for changes in heart rate, blood pressure, anxiety, or other physical sensations.

Caffeine, for example, can independently affect cardiovascular measurements. Other psychoactive substances can also affect heart rate, blood pressure, perception, or anxiety.

The research on combinations with psilocybin is much less developed than the research on psilocybin alone.

For that reason, "there isn't enough evidence to know" is sometimes the most scientifically accurate answer.

A lack of interaction research shouldn't automatically be interpreted as evidence that a combination is dangerous—but it also shouldn't be interpreted as proof that the combination is risk-free.

Should You Monitor Your Blood Pressure While Microdosing?

A home blood-pressure monitor can provide information about your blood pressure at a particular moment, but it cannot establish that microdosing is cardiovascularly safe.

A blood-pressure reading also does not tell you whether your heart valves are healthy or whether another cardiovascular problem is present.

If someone chooses to monitor their blood pressure, measurements should be interpreted in the context of their normal readings and overall health rather than against a supposed "safe microdosing number."

There is currently no scientifically established blood-pressure threshold that tells someone whether it is safe for them to microdose.

If you repeatedly notice unusually high readings or significant cardiovascular symptoms, discuss them with a healthcare professional rather than assuming they are simply part of the microdosing experience.

What If Your Heart Feels Different After a Microdose?

Not every noticeable heartbeat or change in physical sensation indicates a cardiovascular problem. Psychedelics can alter perception and attention, which can make normally unnoticed physical sensations much more noticeable.

At the same time, it is important not to dismiss significant symptoms simply because someone has taken a psychedelic.

Seek appropriate medical attention for symptoms such as:

• Chest pain or pressure

• Fainting or loss of consciousness

• Severe difficulty breathing

• Severe or sustained palpitations

• Significant or persistent dizziness

• New neurological symptoms

• Any other symptom that feels medically urgent

Don't assume that a severe or unusual symptom is "just the microdose."

What Does the Research Actually Tell Us?

Here's the current evidence in plain language:

Question	What the research currently shows
Can psilocybin raise blood pressure?	Yes. Temporary increases have been repeatedly observed in controlled studies. [2–5]
Can psilocybin affect heart rate?	Yes. Heart-rate increases have been observed, although effects appear less consistent than blood-pressure changes. [5–6]
Does microdosing specifically affect blood pressure?	Some microdosing research has reported increased blood pressure, but cardiovascular outcomes have not been measured consistently enough to establish the size or frequency of the effect. [7]
Does microdosing cause heart-valve disease?	No causal relationship has been established. A potential 5-HT2B-related mechanism remains an area of research. [9–11]
Is long-term cardiovascular safety established?	No. Long-term repeated-exposure data remain limited. [1,8]
Are serious cardiovascular events common in clinical psilocybin research?	They have been uncommon in carefully selected, controlled research populations. [3,5]
Does that prove microdosing is cardiovascularly safe?	No. Clinical research conditions, doses, participants, and products can differ substantially from real-world repeated microdosing. [1,5]

The Biggest Question Researchers Still Need to Answer

One of the most important unanswered questions isn't whether psilocybin can temporarily change blood pressure.

We already have evidence that it can.

The bigger question is:

What does repeated, low-level exposure over long periods mean for cardiovascular health?

Answering that question requires studies that follow people for substantially longer periods and measure cardiovascular outcomes directly.

Researchers have suggested approaches such as prospective cohorts, standardized exposure measurements, and cardiac monitoring—including echocardiographic assessment where appropriate—to better understand long-term cardiovascular effects. [8]

This is particularly important because real-world microdosing can involve repeated exposure for months or years, while many controlled studies measure effects over much shorter periods.

Until those studies exist, claims about the long-term cardiovascular safety—or danger—of microdosing should be treated cautiously.

So, Is Microdosing Safe for Your Heart?

The most scientifically accurate answer is:

We don't know enough to say that repeated psilocybin microdosing is completely cardiovascularly risk-free, but current research also does not establish that microdosing causes long-term heart damage.

What we do know is that psilocybin can temporarily increase blood pressure and sometimes heart rate.

What remains uncertain is what repeated low-dose exposure over months or years means for cardiovascular health.

The potential connection between repeated serotonergic stimulation and heart-valve biology is an area researchers continue to investigate, but psilocybin microdosing has not been shown to cause valvular heart disease in clinical research.

For harm reduction, the most useful takeaway isn't to assume that microdosing is either harmless or inherently dangerous.

It's to recognize that "small dose" doesn't necessarily mean "no physiological effect," while also recognizing that a theoretical mechanism isn't the same thing as demonstrated harm.

That distinction is at the heart of responsible psychedelic education.

Frequently Asked Questions

Does microdosing raise blood pressure?

Some microdosing studies have reported increased blood pressure, and larger-dose psilocybin studies consistently show temporary increases in blood pressure. However, researchers do not yet have enough microdosing-specific data to determine exactly how often or how much blood pressure changes during repeated mushroom microdosing. [2,5,7]

Does psilocybin increase heart rate?

It can. Heart-rate increases have been observed in controlled psilocybin studies, although the effect appears less consistent and generally smaller than the increase in blood pressure. [5–6]

Can microdosing cause heart palpitations?

A person may notice their heartbeat or experience cardiovascular sensations after taking psilocybin, but research does not establish that every experience of palpitations is caused by a cardiovascular abnormality. Severe or sustained palpitations should be medically evaluated rather than automatically attributed to microdosing.

Can microdosing damage heart valves?

There is currently no clinical evidence establishing that psilocybin microdosing causes heart-valve disease. Researchers are investigating the possibility because of psilocybin's serotonergic activity and the known relationship between sustained 5-HT2B signaling and valvular disease with certain other drugs. [9–11]

Is microdosing safe if you have high blood pressure?

There isn't enough evidence to establish a universal answer. Because psilocybin can temporarily increase blood pressure, people with hypertension or other cardiovascular conditions should discuss their individual circumstances with a qualified healthcare professional.

Should I monitor my blood pressure while microdosing?

Blood-pressure monitoring can tell you what your blood pressure is at a particular time, but it cannot establish that microdosing is safe or rule out other cardiovascular problems. Repeatedly abnormal readings should be discussed with a healthcare professional.

Does microdosing affect cardiovascular health long term?

Long-term cardiovascular effects remain insufficiently studied. Current reviews identify long-term cardiac safety as an unresolved research question. [1,8]

Are cardiovascular effects different between microdosing and larger doses?

They may be, but researchers do not yet have enough evidence to precisely quantify the difference. Most detailed cardiovascular data come from studies using larger, standardized doses rather than repeated mushroom microdoses. [1,5]

A Note on the Evidence

Research into psychedelic microdosing is still developing. Studies vary substantially in the substances used, dose definitions, preparation methods, dosing schedules, participant populations, and methods used to measure outcomes.

For that reason, this article distinguishes between:

What has been observed: Temporary cardiovascular changes, particularly increases in blood pressure, have been documented following psilocybin administration.

What is plausible but unproven: Repeated serotonergic exposure may warrant investigation for possible long-term cardiovascular effects, including effects involving 5-HT2B signaling.

What has not been established: That psilocybin microdosing causes heart-valve disease or long-term cardiovascular damage.

As better long-term research becomes available, our understanding of these questions may change.

Sources used for the article

1. 2026 systematic review of psilocybin mushroom/truffle microdosing — 11 studies, 3,262 adults; found low-certainty evidence and substantial heterogeneity. (Link)

2. Systematic review of psilocybin tolerability and safety in psychiatric/substance-use research — found modest transient increases in blood pressure and heart rate. (Link)

3. 2024 meta-analysis of psychedelic safety — 30 studies; found increased risk of elevated heart rate and systolic/diastolic BP during the acute phase, with serious events uncommon in controlled settings. (Link)

4. 2024 systematic review/meta-analysis of acute adverse effects of therapeutic-dose psilocybin — found elevated BP was significantly more common following psilocybin than placebo. (Link)

5. 2026 cardiovascular safety review — current synthesis of acute hemodynamics, QTc, 5-HT2B biology, repeated exposure, and product variability; reports approximately 19/8.7 mmHg mean SBP/DBP increases in supervised studies and emphasizes that long-term cardiovascular safety remains an open question. (Link)

6. 2024 pooled safety analysis of psilocybin — provides human cardiovascular data from 85 healthy participants and 113 administrations, including the reported 7% rate of HR >100 bpm at the studied doses. (Link)

7. 2025 systematic review of microdosing side effects — 31 studies; reported increased BP among common physiological effects while emphasizing heterogeneity and limited duration. (Link)

8. 2026 structured psychedelic safety review — specifically identifies long-term cardiac safety as unresolved and discusses the need for prospective long-term monitoring. (Link)

9. 2023 review of chronic psychedelic microdosing and valvular heart disease — discusses the theoretical 5-HT2B concern while emphasizing that long-term safety was poorly characterized. (Link)

10. 2024 review of microdosing, cardiac fibrosis and valvulopathy — examines the proposed 5-HT2B mechanism and emphasizes that the cardiovascular risk of chronic psychedelic microdosing had not been established in controlled studies. (Link)

11. 2026 systematic review of cardiac consequences and 5-HT2B-mediated valvular disease — importantly, found no studies demonstrating psilocybin-induced valvular disease; its evidence concerning valvulopathy was primarily related to other serotonergic substances. (Link)